Published in Pharma Law Weekly, November 2nd, 2004
CollaGenex alleges the defendants' submissions of abbreviated new drug applications (ANDAs) covering their 20 mg tablets of doxycycline hyclate infringe United States patent RE 34,656, of which CollaGenex is the exclusive licensee. CollaGenex is seeking an injunction preventing the defendants from introducing 20 mg tablets of doxycycline hyclate into the market in the United States.
CollaGenex markets its...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly